Autres langues Becton, Dickinson and Company

Actions

BDX

US0758871091

Equipement, fournitures et distribution médicale

Marché Fermé - NYSE 22:00:03 28/08/2026			Varia. 5j.	Varia. 1 janv.
189,52 ^USD	+0,74%		+1,01%	-2,34%

27/08	Becton Dickinson atteint 50 % de recrutement pour son essai clinique en chirurgie mammaire	MT
17/08	Becton, Dickinson and Company annonce la nomination de Gary Sorsher au poste de vice-président exécutif et directeur de la qualité, à compter du 8 septembre 2026	CI

Autres langues

27/08	Becton Dickinson Reaches 50% Enrollment in Breast Surgery Trial
27/08	BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
26/08	BD to Present at Wells Fargo 21st Annual Healthcare Conference
17/08	Becton, Dickinson and Company Announces Management Changes
17/08	Becton Dickinson Names Gary Sorsher as Chief Quality Officer
17/08	BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
17/08	Jeffrey Silvestri to Retire as Senior Vice President, Global Head of Quality of Becton, Dickinson and Company in October 2026
13/08	Becton, Dickinson's Consistent Mid-Single-Digit Organic Growth is 12-18 Months Away, RBC Says
12/08	Becton Dickinson & Co Insider Sold Shares Worth $440,888, According to a Recent SEC Filing
12/08	Becton, Dickinson Completes Enrollment in Trial for Phasix Mesh
12/08	BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
12/08	Becton, Dickinson And Company Completes Enrollment In The PREVENT Clinical Trial Evaluating Phasix Mesh For Incisional Hernia Prevention
07/08	Becton, Dickinson's Fiscal Q3 Results Show Progress Amid Major Headwinds, RBC Says
06/08	Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on January 28, 2025.
06/08	Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on January 27, 2026.
06/08	Becton Dickinson Lifts Full-Year Profit Outlook as Third-Quarter Results Top Views
06/08	Becton, Dickinson and Company Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026
06/08	Becton, Dickinson and Company Updates Revenue Growth Guidance for the Full Year Fiscal 2026
06/08	Stocks Mostly Up Pre-Bell as Investors Weigh Potential Iran-Oman Hormuz Deal, Await More Earnings
06/08	Becton, Dickinson Fiscal Q3 Adjusted Earnings, Revenue Rise; Lifts 2026 Adjusted EPS Guidance
06/08	Becton Dickinson raises lower end of annual profit forecast on drug delivery devices strength
06/08	(BDX) Becton Dickinson Expects Fiscal 2026 Adjusted EPS Range $12.62 to $12.72,vs. FactSet Est of $12.61
06/08	Becton Dickinson: Fiscal Q3 Earnings Snapshot
06/08	Earnings Flash (BDX) Becton, Dickinson and Company Reports Q3 Revenue $4.98B
06/08	Earnings Flash (BDX) Becton, Dickinson and Company Posts Q3 Adjusted EPS $3.23 per Share